Shanghai, China, 24 February 2023 – CardioFlow Medtech has recently obtained registration approval from the Food and Drug Administration, Thailand for its independently developed transcatheter aortic valve implantation (TAVI) solutions, the VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) together with the Alwide® Plus Balloon Catheter (Alwide® Plus).
As a new-generation TAVI product, VitaFlow Liberty™ inherits the unique design of the VitaFlow® Transcatheter Aortic Valve and Delivery System (VitaFlow®), with an upgrade to the delivery system. Its unique and innovative double-reinforced spiral structure allows for fast, stable and accurate release and retrieval, whilst ensuring superior flexibility, non-directionality, and 360-degree bending of the valve segment.
Alwide® Plus is the second-generation product of the Alwide® Balloon Catheter (Alwide®) and received its registration approval from the National Medical Products Administration of China in July 2021. Designed to provide precise inflation sizing, its high burst pressure responds better to severe calcification that is commonly found among patients. Additionally, the Alwide® Plus minimizes pacing time due to its faster inflation and deflation speed. Alwide® Plus has a significantly improved burst pressure and sheath design at the distal end of the catheter, improving the user experience and increasing the safety of intraoperative balloon dilation.
Prior to the successful launch of VitaFlow Liberty™ and Alwide® Plus in Thailand, VitaFlow® and Alwide® had already received marketing approval. Currently, CardioFlow Medtech’s products have entered Colombia, Argentina, Brazil, and Thailand. In the future, CardioFlow Medtech will continue to accelerate the commercialization of innovative products with international competitiveness, introducing TAVI products to more countries and regions with the aim to bring high-quality, universal total solutions for structural heart disease to more patients and physicians worldwide.
About CardioFlow Medtech
Founded in Shanghai in 2015, MicroPort CardioFlow Medtech Corporation (“CardioFlow Medtech”, stock code: 02160.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort®", stock code: 00853.HK), is a leading medical device company in China focusing on research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart disease. The Company’s self-developed second-generation Transcatheter Aortic Valve Implantation (TAVI) product VitaFlow Liberty™ is the world’s only commercialized motorized retrievable system. In addition to the TAVI products, the Company has also established a strategic R&D pipeline covering Transcatheter Mitral Valve (TMV) therapies, Transcatheter Tricuspid Valve (TTV) therapies, surgical valve products and surgical accessories via independent development and collaboration with global partners. At CardioFlow Medtech, we strive to provide integrated therapeutic solutions for patients with heart valve disease, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.
More information is available at www.cardioflowmedtech.com.